Blanche Tamarit
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Correction: VTX-PID as a novel recombinant immunoglobulin G-degrading enzyme (IdeS) for efficient AAV-based gene therapy in participants with neutralizing antibodies: results of the phase I first-in-human NAVIgATE study.
Journal: Frontiers in immunology
Published: June 03, 2026
Liver-directed gene therapy results in amelioration of progressive familial intrahepatic cholestasis type 2 in mice.
Journal: Hepatology communications
Published: March 20, 2026
VTX-PID as a novel recombinant immunoglobulin G-degrading enzyme (IdeS) for efficient AAV-based gene therapy in participants with neutralizing antibodies: results of the phase I first-in-human NAVIgATE study.
Journal: Frontiers in immunology
Published: March 06, 2026
High value of 64Cu as a tool to evaluate the restoration of physiological copper excretion after gene therapy in Wilson's disease.
Journal: Molecular therapy. Methods & clinical development
Published: November 10, 2021
Optimising the IgG-degrading enzyme treatment regimen for enhanced adeno-associated virus transduction in the presence of neutralising antibodies.
Journal: Clinical & translational immunology
Published: June 18, 2021
Correction: Membrane microdomains and cytoskeleton organization shape and regulate the IL-7 receptor signalosome in human CD4 T-cells.
Journal: The Journal of biological chemistry
Published: March 31, 2019
Withdrawal: Interleukin-7 compartmentalizes its receptor signaling complex to initiate CD4 T lymphocyte response.
Journal: The Journal of biological chemistry
Published: February 27, 2019
Membrane microdomains and cytoskeleton organization shape and regulate the IL-7 receptor signalosome in human CD4 T-cells.
Journal: The Journal of biological chemistry
Published: January 19, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026